Aphaia's drug formulation is built around glucose, one of the most abundant and inexpensive materials on Earth. This deliberate strategic choice contrasts with complex, expensive injectables. It positions their treatment to address the 94-97% of eligible patients worldwide who cannot access or afford current therapies, creating a massive market opportunity.

While GLP-1s dominated the obesity narrative, the next wave of innovation is focused on novel mechanisms. Arrowhead's significant fundraise for its siRNA drug highlights investor enthusiasm for approaches that offer complementary benefits, such as preserving muscle mass, signaling a new chapter in obesity treatment.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

The emerging Amylin class of obesity drugs shows a consistently more favorable side effect profile than GLP-1 agonists. While weight loss efficacy may be comparable, the superior tolerability positions Amylin as a strong future competitor, either as a standalone option for sensitive patients or as a backbone for combination therapies.

While GLP-1 has been a known target for a long time, the recent explosion in peptide therapeutics was primarily enabled by solving the historical challenge of poor half-life and exposure. Achieving one- or two-week half-lives through techniques like fatty acid acylation was the critical technological unlock for the field.

Beyond direct physiological changes, GLP-1s help correct underlying physiology, which restores the mental and physical resources needed to maintain fundamentals like sleep, exercise, and nutrition. This secondary effect can be more profound than the drug's primary action.

Aardvark is specifically developing its oral drug for patients who have lost weight on injectable GLP-1s but want to discontinue them while preventing weight regain. This strategy taps into a massive, underserved future market of patients seeking a more convenient, long-term maintenance solution.

Rather than competing head-to-head, Aardvark's preclinical data shows combining its oral drug with a microdose of a GLP-1 injectable achieves 30% weight loss, far exceeding the GLP-1 alone. This positions their drug as a complementary therapy that enhances the existing standard of care.

Unlike most drugs with targeted effects, GLP-1s are remarkable for their broad-based impact. They concurrently improve metabolism, mitochondrial creation, cellular cleanup (autophagy), and inflammation, explaining their profound and varied benefits.